metformin intolerance in Thai diabetic patients Plasma membrane monoamine transporter PMAT SLC29A4 rs3889348 gene polymorphism Metformin intolerance
Conditions
Interventions
Participants discontinuing or reducing the dosage of metformin within six months due to the symptoms,Participants were classified as metformin-tolerant, receiving 2,000 mg or more of metformin for ove
Basic Science,Basic Science
Sponsors
Ratchadapisek Research Funds
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. diagnosed with diabetes mellitus 2. treated with metformin (in the past or currently using) 3. both male and female, 18 years or older
Exclusion criteria
Exclusion criteria: 1. The patients discontinued metformin or have reduced the dosage of metformin due to reasons other than GI side effects, such as renal impairment (eGFR less than 45 mL/min/1.73 m2 calculated by Chronic Kidney Disease Epidemiology Collaboration), metformin-induced lactic acidosis, or vitamin B12 deficiency. 2. patient with irritable bowel syndrome (IBS) 3. patient with inflammatory bowel disease (IBD) 4. Cirrhosis Child-Pugh classification B or C 5. patient with advanced-stage cancer 6. patient with acquired immunodeficiency syndrome 7. pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| genotype of SLC29A4 single-nucleotide polymorphism rs3889348 at enrollment to each group Sanger sequencing | — |
Secondary
| Measure | Time frame |
|---|---|
| use of other drugs that affect PMAT function at enrollment to each group number of drug | — |
Countries
Thailand
Contacts
Public ContactAkarapa Chulacupta
Faculty of Medicine, Chulalongkorn University
Outcome results
None listed